119 related articles for article (PubMed ID: 12099998)
1. Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin.
Hillyard DZ; Cameron AJ; McIntyre AH; Hadden MH; Marshall HE; Johnston N; Jardine AG
Clin Exp Pharmacol Physiol; 2002 Aug; 29(8):673-8. PubMed ID: 12099998
[TBL] [Abstract][Full Text] [Related]
2. Fluvastatin prevents vascular hyperplasia by inhibiting phenotype modulation and proliferation through extracellular signal-regulated kinase 1 and 2 and p38 mitogen-activated protein kinase inactivation in organ-cultured artery.
Sakamoto K; Murata T; Chuma H; Hori M; Ozaki H
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):327-33. PubMed ID: 15591221
[TBL] [Abstract][Full Text] [Related]
3. Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survival.
Musso A; Zocchi MR; Poggi A
Haematologica; 2011 Jan; 96(1):16-23. PubMed ID: 20884711
[TBL] [Abstract][Full Text] [Related]
4. Stimulatory effects of low-dose 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on hepatocyte growth factor-induced angiogenesis: involvement of p38 mitogen-activated protein kinase.
Uruno A; Sugawara A; Kudo M; Satoh F; Saito A; Ito S
Hypertens Res; 2008 Nov; 31(11):2085-96. PubMed ID: 19098381
[TBL] [Abstract][Full Text] [Related]
5. Fluvastatin inhibits angiotensin II-induced nuclear factor kappa B activation in renal tubular epithelial cells through the p38 MAPK pathway.
Gao P; Wu X; Shui H; Jia R
Mol Biol Rep; 2012 Apr; 39(4):4719-25. PubMed ID: 21947850
[TBL] [Abstract][Full Text] [Related]
6. Direct effects of statins on the vascular wall.
Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
[TBL] [Abstract][Full Text] [Related]
7. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Inoue M; Nakamura H
Gastroenterology; 2002 Feb; 122(2):308-17. PubMed ID: 11832446
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the endothelial plasminogen activator system by fluvastatin. Role of Rho family proteins, actin polymerisation and p38 MAP kinase.
Dunoyer-Geindre S; Fish RJ; Kruithof EK
Thromb Haemost; 2011 Mar; 105(3):461-72. PubMed ID: 21174002
[TBL] [Abstract][Full Text] [Related]
9. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
Horiuchi M; Cui TX; Li Z; Li JM; Nakagami H; Iwai M
Circulation; 2003 Jan; 107(1):106-12. PubMed ID: 12515751
[TBL] [Abstract][Full Text] [Related]
10. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
11. Fluvastatin enhances apoptosis in cytokine-stimulated vascular smooth muscle cells.
Takahashi M; Ogata Y; Okazaki H; Takeuchi K; Kobayashi E; Ikeda U; Shimada K
J Cardiovasc Pharmacol; 2002 Feb; 39(2):310-7. PubMed ID: 11791017
[TBL] [Abstract][Full Text] [Related]
12. Fluvastatin inhibits high glucose-induced nuclear factor kappa B activation in renal tubular epithelial cells.
Gao P; Wu X; Shui H; Jia R
J Nephrol; 2013; 26(2):289-96. PubMed ID: 22641573
[TBL] [Abstract][Full Text] [Related]
13. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro.
Rogler G; Lackner KJ; Schmitz G
Am J Cardiol; 1995 Jul; 76(2):114A-116A. PubMed ID: 7604784
[TBL] [Abstract][Full Text] [Related]
14. Fluvastatin inhibits hypoxic proliferation and p38 MAPK activity in pulmonary artery fibroblasts.
Carlin CM; Peacock AJ; Welsh DJ
Am J Respir Cell Mol Biol; 2007 Oct; 37(4):447-56. PubMed ID: 17556673
[TBL] [Abstract][Full Text] [Related]
15. Fluvastatin Upregulates the Expression of Tissue Factor Pathway Inhibitor in Human Umbilical Vein Endothelial Cells.
Sekiya A; Morishita E; Maruyama K; Torishima H; Ohtake S
J Atheroscler Thromb; 2015 Jul; 22(7):660-8. PubMed ID: 25735397
[TBL] [Abstract][Full Text] [Related]
16. Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes.
Hillyard DZ; Jardine AG; McDonald KJ; Cameron AJ
Atherosclerosis; 2004 Feb; 172(2):219-28. PubMed ID: 15019531
[TBL] [Abstract][Full Text] [Related]
17. Fluvastatin attenuates IGF-1-induced ERK1/2 activation and cell proliferation by mevalonic acid depletion in human mesangial cells.
Shibata T; Tamura M; Kabashima N; Serino R; Tokunaga M; Matsumoto M; Miyamoto T; Miyazaki M; Furuno Y; Takeuchi M; Abe H; Okazaki M; Otsuji Y
Life Sci; 2009 May; 84(21-22):725-31. PubMed ID: 19254730
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells.
McGillicuddy FC; O'Toole D; Hickey JA; Gallagher WM; Dawson KA; Keenan AK
Vascul Pharmacol; 2006 Jun; 44(6):469-75. PubMed ID: 16624629
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy.
Ogata Y; Takahashi M; Takeuchi K; Ueno S; Mano H; Ookawara S; Kobayashi E; Ikeda U; Shimada K
J Cardiovasc Pharmacol; 2002 Dec; 40(6):907-15. PubMed ID: 12451324
[TBL] [Abstract][Full Text] [Related]
20. [Fluvastatin induces apoptosis on human tongue carcinoma cell line HSC-3].
Fujiwara K; Tsubaki M; Yamazoe Y; Nishiura S; Kawaguchi T; Ogaki M; Nishinobo M; Shimamoto K; Moriyama K; Nishida S
Yakugaku Zasshi; 2008 Jan; 128(1):153-8. PubMed ID: 18176067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
